Profile data is unavailable for this security.
About the company
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).
- Revenue in USD (TTM)0.00
- Net income in USD-101.63m
- Incorporated2004
- Employees28.00
- LocationOruka Therapeutics Inc855 Oak Grove Ave., Suite 100MENLO PARK 94025United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://orukatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | 169.47m | -84.63m | 1.52bn | 136.00 | -- | -- | -- | 8.97 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.53bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Relay Therapeutics Inc | 8.36m | -297.59m | 1.53bn | 188.00 | -- | 2.50 | -- | 182.74 | -1.75 | -1.75 | 0.0491 | 3.52 | 0.0104 | -- | -- | 32,015.33 | -37.20 | -31.62 | -39.14 | -32.85 | -- | -- | -3,561.43 | -1,130.74 | -- | -- | 0.00 | -- | -60.83 | -- | 1.25 | -- | -24.08 | -- |
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.55bn | 123.00 | -- | 4.65 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.56bn | 60.00 | -- | 5.55 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.57bn | 186.00 | -- | 2.62 | -- | 602.39 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.57bn | 31.00 | -- | 19.52 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.58bn | 28.00 | -- | 3.26 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.60bn | 74.00 | -- | 9.54 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.61bn | 65.00 | -- | 3.38 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.62bn | 317.00 | -- | 2.97 | -- | 19.26 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Agios Pharmaceuticals Inc | 44.79m | -401.27m | 1.64bn | 486.00 | -- | 1.27 | -- | 36.54 | -6.96 | -6.96 | 0.7768 | 22.04 | 0.0282 | 0.1959 | 11.00 | 92,162.55 | -25.26 | -10.38 | -26.90 | -11.09 | 87.22 | -- | -895.86 | -768.40 | 13.39 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.41 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Sionna Therapeutics Inc | 0.00 | -70.68m | 1.68bn | 48.00 | -- | 5.20 | -- | -- | -1.61 | -1.61 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -26.35 | -- | -27.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.69bn | 580.00 | -- | -- | -- | 2.81 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
Data as of Feb 13 2026. Currency figures normalised to Oruka Therapeutics Inc's reporting currency: US Dollar USD
55.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 7.24m | 14.96% |
| Fairmount Funds Management LLCas of 30 Sep 2025 | 3.71m | 7.66% |
| Viking Global Investors LPas of 30 Sep 2025 | 2.67m | 5.51% |
| Deep Track Capital LPas of 30 Sep 2025 | 2.65m | 5.49% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.16m | 4.47% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.01m | 4.16% |
| RTW Investments LPas of 30 Sep 2025 | 1.95m | 4.02% |
| Commodore Capital LPas of 30 Sep 2025 | 1.75m | 3.62% |
| Braidwell LPas of 30 Sep 2025 | 1.38m | 2.86% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 1.33m | 2.76% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
